Ken Griffin
AGMB

Ken Griffin’s AgomAb Therapeutics NV AGMB Stock Holding History

Ken Griffin’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$367K Buy
+35,000
New +$496K ﹤0.01% 10009

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $1.02B AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Ken Griffin's AGMB Position: Q1 2026 in Review

Ken Griffin opened a new position in AgomAb Therapeutics NV (AGMB) in Q1 2026: 35,000 shares worth $367K. The stake represents ﹤0.01% of the portfolio and ranks #10009 among its holdings.

32 funds tracked by Wall St. Rank hold AGMB as of Q1 2026.

  • Ken Griffin held 35,000 shares of AgomAb Therapeutics NV worth $367K as of Q1 2026.
  • AgomAb Therapeutics NV was a new Ken Griffin position in Q1 2026.
  • AgomAb Therapeutics NV made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #10009 holding.
  • 32 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.